You are here


17 - 03 - 2017

Lille: new drug against tuberculosis

Researchers from Lille (Inserm, University, Pasteur, CNRS) have succeeded in suppressing antibiotic resistance to ethionamide in the tubercle bacillus.

About one out of every two cases of multidrug-resistant tuberculosis in the world lead to death. Ethionamide is an antibiotic activated by the tubercle bacillus. In the event of resistance, this bioactivation no longer takes place. The researchers managed to recreate this bioactivation with a substance called SMARt-420: mice infected with an ethionamide-insensitive tubercle bacillus were treated efficiently with the combination of ethionamide and SMARt-420.

This drug is under development and the concept will be applied in the research against other antibiotic resistance.